SCHEMBL24782865

SCHEMBL24782865

CCNc1cncc(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
SLC22A8 Q8TCC7 1/20 0.42
SLC22A12 Q96S37 1/20 0.42
SLC22A11 Q9NSA0 1/20 0.42
TAS2R14 Q9NYV8 1/20 0.42
TRPA1 O75762 3/20 0.40
AR P10275 2/20 0.40
KIF11 P52732 1/20 0.39
PTPN5 P54829 1/20 0.37
SCN10A Q9Y5Y9 1/20 0.36
PIK3CD O00329 1/20 0.35
XPO1 O14980 1/20 0.34
DAO P14920 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17700260 0.82 CYP3A4 (0.43) CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12
SCHEMBL11901065 0.81 CYP3A4 (0.42) CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12
SCHEMBL17700603 0.81 CYP3A4 (0.42) CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12
SCHEMBL30401549 0.81 CYP3A4 (0.40) CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12
SCHEMBL7665646 0.79 CYP3A4 (0.45) CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12
SCHEMBL4966922 0.78 TRPA1 (0.53) TRPA1PTPN5XPO1
Hydrochloric Acid SCHEMBL28527606 0.77 CYP3A4 (0.44) CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12
SCHEMBL30137071 0.76 SLC22A12 (0.55) CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12
SCHEMBL29873215 0.76 L3MBTL1 (0.45) CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12
Propionic Acid SCHEMBL28228814 0.75 TAS2R14 (0.44) CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 US disclosed
EP-4104861-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2022-12-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 CYP3A4 4734/4885CYP2C9 4840/4885SLC22A6 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.